Elsevier eBooks, Год журнала: 2024, Номер unknown, С. 265 - 284
Опубликована: Окт. 4, 2024
The Egyptian Journal of Neurology Psychiatry and Neurosurgery, Год журнала: 2024, Номер 60(1)
Опубликована: Июнь 14, 2024
Abstract Alzheimer’s disease (AD) is a neurodegenerative condition that causes cognitive decline, memory loss, and reduced personal autonomy. The pathology of AD involves the aggregation abnormal brain proteins, specifically beta-amyloid plaques tau tangles, disrupting neuronal communication leading to loss cells. Aducanumab, monoclonal antibody, demonstrates promise in clinical trials by selectively binding aggregated amyloid-beta, notable decrease plaque burden potential benefits. However, regulatory approval for aducanumab remains controversial. Lecanemab donanemab are recent additions AD’s treatment landscape, both targeting amyloid-beta. shares similarities with its mechanism action, while employs distinct approach specific truncated form Positive outcomes have been observed early-stage drugs, demonstrating reduction amyloid-beta plaques. While aducanumab’s offers hope treatment, ongoing studies on lecanemab imperative comprehensive understanding their modification. Here, we show this review treatments, focus primary action ultimately giving broader insight topic. emphasizes necessity long-term efficacy safety data assess overall impact these drugs decline functional future researchers endeavor. In conclusion, development antibodies represents significant stride demanding further investigation ascertain true role therapeutic arsenal challenging condition.
Язык: Английский
Процитировано
9
Ageing Research Reviews, Год журнала: 2024, Номер 99, С. 102408 - 102408
Опубликована: Июль 3, 2024
Язык: Английский
Процитировано
5
Molecules, Год журнала: 2024, Номер 29(21), С. 5131 - 5131
Опубликована: Окт. 30, 2024
The most prevalent chronic neurodegenerative illness in the world is Alzheimer's disease (AD). It results mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial psychological impact on relatives of patients. review discusses various pathophysiological mechanisms contributing to AD, amyloid beta, tau protein, inflammation, other factors, while emphasizing need for effective disease-modifying therapeutics that alter progression rather than merely alleviating symptoms. This mainly covers medications are now being studied clinical trials or recently approved by FDA fall under treatment (DMT) category, alters targeting underlying biological DMTs focus improving patient outcomes slowing decline, enhancing neuroprotection, supporting neurogenesis. Additionally, amyloid-targeting therapies, tau-targeting neuroprotective others. evaluation specifically looked at studies FDA-approved novel Phase II III development were carried out between 2021 2024. A thorough US government database identified biologics small molecule drugs 14 agents I, 34 II, 11 might be completed 2028.
Язык: Английский
Процитировано
5
Life, Год журнала: 2025, Номер 15(4), С. 549 - 549
Опубликована: Март 27, 2025
As the leading cause of dementia, Alzheimer’s disease (AD) remains one most pressing global health challenges, affecting millions worldwide and placing an immense burden on healthcare systems caregivers [...]
Язык: Английский
Процитировано
0
Frontiers in Neurology, Год журнала: 2024, Номер 15
Опубликована: Окт. 29, 2024
Neuroinflammation is a central feature in the pathophysiology of several neurodegenerative diseases, including MS, AD, and PD. This review aims to synthesize current research on role inflammation these conditions, emphasizing potential inflammatory biomarkers for diagnosis treatment. We highlight recent findings mechanisms neuroinflammation, utility disease differentiation, implications therapeutic strategies. Advances understanding pathways offer promising avenues developing targeted interventions improve patient outcomes. Future should focus validating larger cohorts integrating them into clinical practice enhance diagnostic accuracy efficacy.
Язык: Английский
Процитировано
3
Biomedicines, Год журнала: 2024, Номер 12(5), С. 1096 - 1096
Опубликована: Май 15, 2024
Alzheimer’s disease, the most common type of dementia worldwide, lacks effective disease-modifying therapies despite significant research efforts. Passive anti-amyloid immunotherapies represent a promising avenue for disease treatment by targeting amyloid-beta peptide, key pathological hallmark disease. This approach utilizes monoclonal antibodies designed to specifically bind amyloid beta, facilitating its clearance from brain. review offers an original and critical analysis exploring several aspects. Firstly, mechanisms action these are reviewed, focusing on their ability promote Aβ degradation enhance efflux central nervous system. Subsequently, extensive history clinical trials involving is presented, initial efforts using first-generation molecules leading mixed results recent clinically approved drugs. Along with undeniable progress, authors also highlight pitfalls this offer balanced perspective topic. Finally, based potential limitations, future directions therapeutic strategy emphasized.
Язык: Английский
Процитировано
2
Journal of Orthopaedic Surgery and Research, Год журнала: 2024, Номер 19(1)
Опубликована: Июль 31, 2024
Osteosarcoma is a primary bone tumor lacking optimal clinical treatment options. Tumor-associated macrophages in the microenvironment are closely associated with development and metastasis. Studies have identified macrophage receptor collagenous structure (MARCO) as specific expressed macrophages. This study aimed to investigate whether anti-MARCO mAb can induce polarization elicit anti-tumor effects. THP-1 cells were treated 20 ng/mL phorbol 12-myristate 13-acetate 80 interleukin-4 for 48 h alternatively activated (M2). Enzyme-linked immunosorbent assay, real-time quantitative polymerase chain reaction, flow cytometry, bioinformatic analyses performed evaluate polarization. The co-culture groups included blank group, an M2 U2OS mAb-treated group. Cell viability assays, cell scratch tests, apoptosis, cycle determine effects of on osteosarcoma cells. It was demonstrated that drive toward classically (M1) Anti-MARCO promoted secretion pro-inflammatory factors by macrophages, including necrosis factor-alpha (TNF-α), interleukin-1beta, interleukin-6 interleukin-23. vitro models revealed suppress growth migration cells, inhibit progression through M1 vitro. exerts anti-osteosarcoma affecting offering potential new therapeutic approach treating osteosarcoma.
Язык: Английский
Процитировано
2
Pharmaceuticals, Год журнала: 2024, Номер 17(8), С. 1061 - 1061
Опубликована: Авг. 13, 2024
This study aimed to provide scientific data on the anti-Alzheimer’s disease (AD) effects of phenolic compounds from Drynariae Rhizoma (DR) extract using a multi-component approach. Screening DR extracts, fractions, and ten isolated against key AD-related enzymes acetylcholinesterase (AChE), butyrylcholinesterase (BChE), β-site amyloid precursor protein cleaving enzyme 1 (BACE1), monoamine oxidase-B (MAO-B) confirmed their significant inhibitory activities. The was have BACE1-inhibitory activity, ethyl acetate butanol fractions were found inhibit all enzymes, including BACE1, AChE, BChE, MAO-B. Among compounds, (2) caffeic acid 4-O-β-D-glucopyranoside, (6) kaempferol 3-O-rhamnoside 7-O-glucoside, (7) 3-o-b-d-glucopyranoside-7-o-a-L-arabinofuranoside, (8) neoeriocitrin, (9) naringin, (10) hesperidin significantly suppressed enzymes. Notably, 2 8 reduced soluble Amyloid Precursor Protein β (sAPPβ) β-secretase expression by over 45% at concentration 1.0 μM. In thioflavin T assay, 6 7 decreased Aβ aggregation approximately 40% 80%, respectively, degraded preformed aggregates. provides robust evidence regarding potential as natural therapeutic agent for AD, highlighting specific that may contribute its efficacy.
Язык: Английский
Процитировано
2
Опубликована: Апрель 8, 2024
Background With few effective treatments, Alzheimer's disease (AD) represents a substantial worldwide health burden. Potential disease-modifying treatments have gained attention due to recent developments in immunotherapy that target TAU protein. The purpose of this thorough analysis is investigate the safety and efficacy protein antibodies treatment AD. Methodology This review investigates as possible for Using variety databases, literature search was carried out with an emphasis on clinical trials academic publications regarding Predetermined criteria were used select eligible studies, pertinent data then retrieved compiled. PRISMA guidelines transparency followed reporting. Conclusion shown some potential treating disease, including little improvement cognitive deterioration. Safety considerations highlight need cautious interpretation, especially regard imaging abnormalities amyloid. Optimizing efficacy, safety, cost-effectiveness requires further studies.
Язык: Английский
Процитировано
1
bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown
Опубликована: Ноя. 15, 2024
Abstract We recently reported development of human MAPT knock-in mice that carry single or double pathogenic mutations frontotemporal dementia. However, it takes more than 14 months for the line with most aggressive phenotypes to exhibit tau pathology without forming high-order oligomers, along concomitant abnormal behavior. thus generated carrying triple mutations, among which P301S;Int10+3;S320F exhibited robust starting earlier 6 months. Tau accumulation took place mainly in thalamus, hypothalamus, amygdala and entorhinal cortex, but less so hippocampus, leading synaptic loss, atrophy behavioral abnormalities. Crossbreeding App NL-G-F resulted manifestation hippocampus cortex. These mutant will be valuable tools understanding mechanisms dementia, Alzheimer’s disease other tauopathies.
Язык: Английский
Процитировано
1